RecruitingNCT06767462
An Ophthalmic Safety Study in Patients With Breast Cancer
A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer
Sponsor
AstraZeneca
Enrollment
160 participants
Start Date
Mar 4, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Eligibility
Min Age: 18 YearsMax Age: 130 Years
Inclusion Criteria4
- Signed informed consent in the qualifying study.
- Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
- Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
- Meets all the eligibility criteria in the qualifying study
Exclusion Criteria3
- Patients not randomized and not receiving study assigned treatment in a qualifying study.
- Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
- Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Locations(75)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06767462